




RealRate

PHARMACEUTICAL 2018

Enveric Biosciences Inc.
Rank 108 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Enveric Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enveric Biosciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 420% points. The greatest weakness of Enveric Biosciences Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 352% points.

The company's Economic Capital Ratio, given in the ranking table, is -46%, being 231% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	14,645
Cost of Goods Sold	38,356
Intangible Assets	31,368
Liabilities, Current	30,368
Liabilities, Non-Current	2,381
Other Assets	6,089
Other Compr. Net Income	-2,045
Other Expenses	1,307
Other Liabilities	0
Other Net Income	504
Property and Equipment	95
Research and Development	0
Revenues	48,594
Selling, General and Administrative Expense	18,510

Output Variable	Value in 1000 USD
Assets	52,197
Liabilities	32,748
Expenses	58,173
Stockholders Equity	19,448
Net Income	-9,075
Comprehensive Net Income	-10,097
Economic Capital Ratio	-46%